



IDT Australia

INTERIM RESULTS FY2026

- Cov - 2
e / Vacuna
/ Impfstoff
250 ml

SARS - Cov - 2
Vaccine / Vacuna
Vaccin / Impfstoff
250 ml

SARS - Cov - 2
Vaccine / Vacuna
Vaccin / Impfstoff
250 ml

SARS - Cov - 2
Vaccine / Vacuna
Vaccin / Impfstoff
250 ml

SARS - Cov - 2
Vaccine / Vacuna
Vaccin / Impfstoff
250 ml

Disclaimer and Important Notices

This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant, or which a prospective investor may require in evaluating for a possible investment in the Company. Prospective investors should not rely on the information contained in this presentation and must satisfy themselves as to the accuracy of all such information. This presentation has been prepared based on information available at the time of preparation and is subject to change without notice. In receiving this presentation, each recipient agrees to the foregoing terms and conditions, including any modifications to them. No person is under any obligation to update this presentation at any time after its release.

This presentation is provided for general information purposes only. This presentation does not constitute an offer, invitation, solicitation, or recommendation with respect to the purchase or sale of securities in the Company in any jurisdiction. It is not a prospectus, product disclosure statement, pathfinder document, or any other type of public offer disclosure document for the purposes of the Corporations Act 2001 (Cth) (Corporations Act) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission. It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company.

This presentation does not constitute investment or financial product advice. It is not intended to be used as the basis for making a financial decision, nor is it intended to constitute legal, tax, accounting, or other advice. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives, and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits, or any other legal commentary (if any) are indicative only, do not summarise all relevant issues, and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections, or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (Forward Statements). Forward Statements can generally be identified by the use of forward-looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance, or outlook on future revenues, distributions or financial position and performance or return on growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. To the extent that certain statements contained in this presentation may constitute 'Forward Statements' or statements about forward looking matters, then the information reflects the Company's (and no other party's) intent, belief, or expectations as at the date of this presentation. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate, and their respective officers, directors, employees, advisers, partners, affiliates, and agents (together, the IDT Australia Parties) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in Australian dollars (\$) or A\$) unless otherwise stated.

An investment in the Company's securities is subject to known and unknown risks, many of which are beyond the control of the Company, including factors and risks specific to the industry in which the Company operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return or the performance of the Company, nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company. By accepting this presentation, the recipient agrees to keep permanently confidential all information that it contains. It should not be made available to any other third party without the prior written approval of the Company. Furthermore, no contact should be made with the Company or any of its customers, suppliers or shareholders or any of the IDT parties, without the express permission of the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. The presentation is not an offer of securities in the Company for subscription, purchase or sale in any jurisdiction outside Australia, including the United States or in relation to any US person (as defined in Regulation S under the U.S Securities Act of 1933, as amended). Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director, partner or in the employment of the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the IDT Australia Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information.

To the maximum extent permitted by law, the IDT Australia Parties:

- exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and
- make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

H1FY26 Result Highlights

Strategic Realignment Under New Leadership



Earnings Recovery

A \$2.3M increase in EBITDA to a modest loss of \$436K & Normalised EBITDA of -\$256K (ex one-off redundancy costs)



Operating Revenue Increase

Revenue from three verticals (ex low-margin disbursements) jumped 20.3% PCP to \$8.4M.




Standout Performers

Revenue growth due to strong growth in API Manufacturing and Specialty Orals businesses.



Operating Costs Improvement

Operating expenses reduced by \$1.1M or 14% PCP driven by resource reallocation and early automation benefits



Savings Target Exceeded

On track for annualised cost savings of \$2M (vs. original target of ~\$1M)



Positive Outlook

Early results from strategic realignment reinforces the positive full year outlook

Strategic Reset

Addressing Recent Operational & Financial Challenges



Targeting clients with resources & pipeline for follow-on work



Reallocating resources to opportunities that strongly align with IDT's expertise and capacity




Digitisation, automation & AI initiatives expected to deliver savings and efficiencies in the future



Exploring new revenue streams that leverage IDT's core competencies

Encouraging Early Results



H1FY26 Financial Performance

Returning to Profitability

	H1FY26	H1FY25	% Chg
REVENUE FROM 3 VERTICALS	\$8.4M	\$7.0M	+20.3%
<i>Composition:</i>			
- API	35.4%	14.7%	
- Specialty Orals	30.0%	56.4%	
- Sterile Fill (Adv Therapies)	34.6%	28.9%	
DISBURSEMENTS/OTHER	\$1.4M	\$3.5M	-61.4%
TOTAL REVENUE	\$9.8M	\$10.5M	-7.1%
EBITDA	-\$0.4M	-\$2.7M	+83.8%
NORMALISED EBITDA	-\$0.3M		

▶ Ordinary revenue growth in the period was driven by API and Specialty Orals businesses

▶ More balanced revenue split between the 3 verticals

▶ Improved operating margins reflecting improved customer and revenue mix


▶ Disbursements are costs that are charged back to clients with a low margin

▶ Total expenses declined \$2.2M or 19.5% PCP

▶ Excluding one-off redundancy costs of \$180K

Cost Optimisation Upgrade

Doubling in Annualised Cost Savings Target



Expected annualised **cost savings of \$2M** (vs. initial target of ~\$1M) from FY26.

Total Expenses in H1FY26 **down 20% PCP** to \$9.0M, while Operating Expenses **dropped 14% PCP** to \$6.6M. The savings are driven by:


- ▶ Organisational restructuring and reduction in headcount
- ▶ Use of internal expertise on capital projects instead of external consultants
- ▶ Digitisation and automation of some manufacturing processes
- ▶ Other continuous improvement initiatives

Performance Breakdown

Returning to Profitability

Vertical	Rev	% Chg	Comments
API Manufacturing	\$3.0M	+191.4%	Reestablishing this business as foundation of growth and targeting clients with potential for follow-on contracts to other 2 businesses. The strong performance bodes well for the other verticals.
Specialty Orals	\$2.5M	+25.8%	Changing primary focus to growing radiopharmaceutical industry and away from more commoditised medicinal cannabis and psychedelics.
Sterile Fill (Adv Therapies)	\$2.9M	-25.7%	Decline due to timing of customer projects, with activity expected to normalise in H2. IDT is a leading Australian mRNA manufacturer and there's strong growing demand for mRNA innovations.

Interim Revenue Breakdown



Three Business Verticals

Re-establishing API Vertical as Foundation for Growth



Active Pharmaceutical Ingredient (API) Manufacture

- Legacy business and a key strength of IDT
- Acts as sales funnel for flow-on work to other 2 verticals to create the finished drug
- Development and manufacturing of the active ingredient in drugs
- Scalable production from 1mg to 1000KG – covering R&D to commercial quantities
- Globally expanding existing API assets



Specialty Orals

- Production of capsules, tablets and liquids
- Primary focus on high-margin radiopharmaceuticals amid rising demand
- Secondary focus on supporting more commoditised psychedelics and medcan innovations
- Up to 50K capsules or 10K tablets per hour



Sterile Fill (Advanced Therapies)

- Purpose built high containment sterile facility
- Global shortage of such specialised capabilities
- IDT is Australia's first mRNA vaccine manufacturer
- Produced >20 mRNA drugs to date
- Growth in radiopharmaceuticals amid rising demand
- Clinical to commercial scale production – up to 200K vials/week from 2mL to 20mL

mRNA & Radiopharmaceutical

Key Growth Opportunities



- ➔ First cGMP in-human mRNA vaccine clinical supplier in Australia
- ➔ Leading mRNA vaccine clinical supplier in the southern hemisphere
- ➔ mRNA development partnerships with leading global pharma organisations
- ➔ Global mRNA market forecast to hit US\$26.1B by 2034 (18.2% CAGR)¹
- ➔ Tested & delivered results in radiopharmaceuticals from clinical to commercial supply
- ➔ Global radiopharmaceutical market expected to reach US\$21.9B by 2029 (16.4% CAGR)²

1) <https://www.fortunebusinessinsights.com/mrna-therapeutics-market-113411>

2) <https://blog.bccresearch.com/radiopharmaceuticals-market-to-double-by-2029-heres-why>

Further Gains Expected

Building on the Early Momentum

Positioned for Growth

- ▶ Solid pipeline across all business units
- ▶ Strongly positioned to capitalise on growing mRNA and Radiopharmaceutical innovations
- ▶ Room for growth with current plant utilisation fluctuating from 20%-35% depending on manufacturing cycles (based purely on one shift and commissioned facilities, not entire site).

Operating Leverage

- ▶ Doubling of annualised cost savings target to \$2M
- ▶ Additional savings potential from further automation/AI investments
- ▶ Streamlined business can support further growth with only marginal increase in opex
- ▶ Improved working capital profile and facility headroom to drive identified growth initiatives

Benefits from Strategic Reset

- ▶ Focus on achieving a positive operating profit in the near-term
- ▶ Better client targeting for repeat and flow-on work
- ▶ Reallocation of resources yielding early positive results
- ▶ Further gains expected in the coming periods

Competitive Advantage

- ▶ Market leader and one of a few TGA/FDA/APVMA licensed facilities in the region
- ▶ ~\$100M in tangible assets (building, land, licenses)
- ▶ End-to-end services (development, manufacturing, QC, QA, packaging, labelling, distribution)

Board of Directors

Experienced Board and Leadership Team



Mark Simari
Executive Chair

Mark Simari is an experienced and accomplished professional in the health industry and has over 15 years' Board experience in a diverse range of organisations. Mark was the former managing director and co-founder of Paragon Care (between 2008 and 2018). He was instrumental in Paragon Care becoming one of the largest independent healthcare suppliers in Australian and New Zealand Market, creating a healthcare platform spanning across capital equipment, consumables, devices and service and maintenance.



Geoffrey Sam, OAM
Non-Executive Director

Geoffrey Sam brings with him a wealth of healthcare experience and accomplishments. He is currently Chairperson and Independent non-executive Director at Earlypay Ltd (ASX:EPY) and Paragon Care Ltd (ASX:PGC) since 2016. He is the Co-Founder and Board member of Health Care Australia Pty Ltd, a privately owned healthcare company comprising a portfolio of 14 hospitals.



Jane Ryan
Non-Executive Director

Dr Jane Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries where she has held executive roles in Management of Research and Development programs, as well as Business Development and Alliance Management. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives including the winning of a \$230 million US Government contract. Jane is also currently on the board of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Viral Vector Manufacturing Facility.

A modern, white, multi-story building with large glass windows and a flat roof. Three flags are flying on poles in front of the building: the Australian flag, the New Zealand flag, and a blue flag with a white emblem. The building is surrounded by green trees and a clear blue sky.

IDT Australia

Investor & Media Enquiries:

Brendon Lau

e: brendon@vantagepointpartners.com.au

m: 0409 341 613